All News
📢#ACR21 #Abstr1421 Is #COVID19 vaccine safe and effective in #lupus? YES!! VOCOLUP study (N=1189 pts) showed:
💠~45% had a side-effect; of which 80% mild/moderate
💠Only 3% flared post💉(MSK + Fatigue); 10 required hospitalisation @RheumNow #ACRBest https://t.co/WF4aAfiX70 https://t.co/jc0HQoJymo
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR21 #Abstr1083 Do pts with Autoinflammatory disease flare differently during #COVID19? Survey of N=647 (mostly CAPS):
💠56% No change
💠Of pts who flared, 50% had low/absent fever
💠7% had COVID; mostly mild
Shielding could influence results @RheumNow https://t.co/g7VazLfiT9 https://t.co/lzaSoMEzyR
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
ACR21 Best Abstracts - Day 2
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).
Read Article
ACR21 Best Abstracts - Day 1
The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.
Read Article
Dr FCardwell et al on Health Info use in SLE pts b4 and during COVID19 using an online survey
🦋#lupus specialists & fam physicians - ⬆preferred & trusted health info sources but access to them ⬇frequent during covid19
A call to action?📢
@RheumNow #ACR21 abs0880 @rheumarhyme https://t.co/1NBEAlFvHx
sheila RHEUMarampa ( View Tweet)
Awesome interview w/ @rheum_cat @JYazdanyMD @jeffsparks
video link https://t.co/dVLayNchHT
TheDaoIndex KDAO2011 ( View Tweet)
Please don’t miss MISC (pronounced Miss C)=multisystem inflammatory syndrome. Pediatric syndrome post #SARSCoV2 infection. May go w macrophage activation syndrome (MAS) w distinct proteomics signature. Potentially v poor outcomes. Need to dx and treat #ACR21 abst0961 @RheumNow https://t.co/uaBbUdg3lt
Janet Pope Janetbirdope ( View Tweet)
Dr. Petri on COVID19 infection vs vaccination on SLE activity:
💠Infection = NO increase SLE activity
💠Infection =⬇️ cutaneous activity
💠Infection = ⬆️anti-cardiolipin IgG/M
💠Vaccination: no increase in activity NOR aCL IgG/M
https://t.co/fWbotSLS3o
#ACR21 Abst#0858 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Abstr 0983 mRNA SARS-CoV-2 Vaccine in RA Patients
Rubbert-Roth and colleagues found:
- RA patients developed anti-S1 antibodies slower and lower compared to controls
- Reduced titers among Abatacept & JAKi users
#ACR21 @RheumNow https://t.co/sXW8d53O8m
Akhil Sood MD AkhilSoodMD ( View Tweet)
#ACR21 #Abstr0866 Data from #COVID19 GRA Registry showed predictors of poor COVID outcome in 1922 #lupus pts:
Older age
Male
Areas outside Europe, 🇺🇸🇨🇦
Infection <June 2020
Any Corticosteroid dose
Not on therapy
On Rituximab
Comorbidities
⬆️disease activity
@RheumNow #ACRBest https://t.co/u0GF3aDsFA
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR21 #Abstr0858 Petri reported effect of #COVID and vaccination in #lupus cohort
💠No increase in activity post-infection
💠⬇️cutaneous activity
💠⬆️ aCL IgG and IgM post-infection,
💠No increase in SLE activity or aCL abs post-vaccination
@RheumNow https://t.co/iAaIfzf33c https://t.co/hA6sk6icrs
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Andy 0963 #ACR21 @RheumNow covid19 vaccine immunogenicity in rheum pts overall good at 71%, fairly dependent on Rx choice: rituximab 38% after 1g & only 7 % after 1gx2; abatacept IV 45%. Rest biologics >80%, ⬇️MTX &MMF. Low dose prednisone w/out biologics did not affect Ab+ rates https://t.co/TkCC1sgMHG
Olga Petryna DrPetryna ( View Tweet)
Infx oral session
0964 Bitoun, et al.
RTX lowers neutralizing Ab response compared to healthy controls, after COVID vaccination -- more supportive data
https://t.co/6jvWHSjIgr
#ACR21
Rheum Cat rheum_cat ( View Tweet)
Outcomes of COVID-19 in Patients with Rheumatoid Arthritis.
Dr. Akhil Sood ( @AkhilSoodMD) shares the studies presented #ACR21.
https://t.co/yrs8N8XSiS https://t.co/EKHuTS5aDr
Links:
Dr. John Cush RheumNow ( View Tweet)
Results from @rheum_covid on #COVID19 outcomes in patients with #vasculitis #Abs0952 #ACR21
👉🏼~1000 pts
👉🏼Severe outcomes esp in #GCA and #AAV
👉🏼Older age, comorbidities, disease activity, high-dose steroids assoc with worse outcomes
@RheumNow
https://t.co/e2UlgDpyjw https://t.co/skoTKVYbEL
Mrinalini Dey DrMiniDey ( View Tweet)
‘Cool’ explanation for #COVID toes. Type I IFN response can drive perniosis. Great session of cases from Len Calabrese & Jack Cush @RheumNow #ACR21 7S001 usual suspects https://t.co/v8IX2xxOZ7
Janet Pope Janetbirdope ( View Tweet)
@SattuiSEMD presents @rheum_covid data on COVID-19 outcomes in vasculitis/PMR. High rates of severe outcomes, particularly for AAV and GCA (mortality >20% for both). Multiple factors associated with outcomes (see below). Abstr#952 #ACR21 @RheumNow #ACRBest https://t.co/0lw1QhuJct
Richard Conway RichardPAConway ( View Tweet)
So important for our systemic vasculitis & PMR pts, @rheum_covid data highlighting the outsized COVID-19 risks they face.
Thanks @SattuiSEMD @RichardPAConway @EBRheum in particular for driving forward this badly needed work!
#ACR21 ABST0952 @RheumNow https://t.co/L7XS9OblxI https://t.co/LYxR1WUlhM
David Liew drdavidliew ( View Tweet)
Factors associated w/ poor COVID19 outcomes in #SLE from the GRA @rheum_covid
📌Demographics - age, sex, region
📌Glucocorticoid use
📌 Comorbids - renal, CV
📌Untreated/active dse
❗Very important msg here: Control dse, manage comorbids & avoid GCs
@RheumNow #ACR21 abs0866 https://t.co/eXR3KqGrJa
sheila RHEUMarampa ( View Tweet)
Good news for #COVID vaccine in #SLE. ✅doesn’t cause #lupus flares ➡️ no increase in APS. What about #SARS-CoV2 infection in SLE. Flares ↔️ stable but ⬆️APS Abs. from Hopkins cohort. Petri #ACRBest #ACR21 abst0858 @RheumNow https://t.co/ABx4C4lwvs
Janet Pope Janetbirdope ( View Tweet)